PL145663B1 - Method of obtaining sustained-action drug tablets - Google Patents
Method of obtaining sustained-action drug tablets Download PDFInfo
- Publication number
- PL145663B1 PL145663B1 PL1985252062A PL25206285A PL145663B1 PL 145663 B1 PL145663 B1 PL 145663B1 PL 1985252062 A PL1985252062 A PL 1985252062A PL 25206285 A PL25206285 A PL 25206285A PL 145663 B1 PL145663 B1 PL 145663B1
- Authority
- PL
- Poland
- Prior art keywords
- polyvinyl butyral
- active substance
- tablets
- release
- granulate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 239000003814 drug Substances 0.000 title description 3
- 229940079593 drug Drugs 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 claims description 38
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 25
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 10
- 229960000541 cetyl alcohol Drugs 0.000 description 9
- 239000000454 talc Substances 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001012 codeine hydrochloride Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU84686A HU191246B (en) | 1984-02-21 | 1984-02-21 | Process for producing oral pharmaceutical compositions of retaed activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL252062A1 PL252062A1 (en) | 1985-12-03 |
| PL145663B1 true PL145663B1 (en) | 1988-10-31 |
Family
ID=10950851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1985252062A PL145663B1 (en) | 1984-02-21 | 1985-02-21 | Method of obtaining sustained-action drug tablets |
Country Status (10)
| Country | Link |
|---|---|
| BG (1) | BG51340A3 (ru) |
| CS (1) | CS251786B2 (ru) |
| DD (1) | DD231985A5 (ru) |
| HU (1) | HU191246B (ru) |
| IT (1) | IT1185513B (ru) |
| PL (1) | PL145663B1 (ru) |
| RO (1) | RO93562B (ru) |
| SU (1) | SU1720474A3 (ru) |
| WO (1) | WO1985003636A1 (ru) |
| YU (1) | YU45233B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204294B (it) * | 1986-03-11 | 1989-03-01 | Gentili Ist Spa | Metodo di fabbricazione di granulari atti a produzione di compresse rivestite,per uso orale,a rilascio controllato |
| EP0565560B1 (en) * | 1991-01-03 | 1994-09-28 | Glaxo Canada Inc. | Method for production of solid pharmaceutical preparation |
| HUT72408A (en) * | 1993-09-10 | 1996-04-29 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablets containing acetyl-salicylic acid |
| US6258381B1 (en) * | 2000-02-11 | 2001-07-10 | Mcneil-Ppc, Inc. | Tablet and process for making the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919436A (en) * | 1971-09-27 | 1975-11-11 | Eisai Co Ltd | Process for preparation of coated medicines |
| DE2347713C3 (de) * | 1972-09-25 | 1980-03-06 | Warner-Lambert Co., Morris Plains, N.J. (V.St.A.) | Acetylsalicylsäurekautablette |
| DE2446058A1 (de) * | 1974-09-26 | 1976-04-08 | Henning Berlin Gmbh | Galenische zubereitung fuer die allopurinol-dauertherapie |
| JPS5837285B2 (ja) * | 1975-05-29 | 1983-08-15 | カブシキガイシヤ ミドリジユウジ | チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ |
-
1984
- 1984-02-21 HU HU84686A patent/HU191246B/hu not_active IP Right Cessation
-
1985
- 1985-02-14 RO RO120458A patent/RO93562B/ro unknown
- 1985-02-14 WO PCT/HU1985/000008 patent/WO1985003636A1/de unknown
- 1985-02-20 DD DD85273425A patent/DD231985A5/de not_active IP Right Cessation
- 1985-02-21 IT IT8519584A patent/IT1185513B/it active
- 1985-02-21 YU YU266/85A patent/YU45233B/xx unknown
- 1985-02-21 PL PL1985252062A patent/PL145663B1/pl unknown
- 1985-02-21 CS CS851278A patent/CS251786B2/cs unknown
- 1985-10-17 SU SU853965111A patent/SU1720474A3/ru active
- 1985-10-21 BG BG072090A patent/BG51340A3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS251786B2 (en) | 1987-08-13 |
| IT8519584A0 (it) | 1985-02-21 |
| RO93562B (ro) | 1988-01-02 |
| WO1985003636A1 (en) | 1985-08-29 |
| DD231985A5 (de) | 1986-01-15 |
| BG51340A3 (en) | 1993-04-15 |
| HUT37356A (en) | 1985-12-28 |
| IT1185513B (it) | 1987-11-12 |
| HU191246B (en) | 1987-01-28 |
| CS127885A2 (en) | 1986-12-18 |
| RO93562A (ro) | 1987-12-31 |
| PL252062A1 (en) | 1985-12-03 |
| YU45233B (en) | 1992-05-28 |
| YU26685A (en) | 1988-02-29 |
| SU1720474A3 (ru) | 1992-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2738936B2 (ja) | 被覆徐放製剤 | |
| RU2095054C1 (ru) | Твердая лекарственная форма для орального введения | |
| US5662935A (en) | Process for preparing controlled release pharmaceutical forms and the forms thus obtained | |
| EP0532611B1 (en) | Process for the manufacture of porous cellulose matrices | |
| JP2862222B2 (ja) | ｐＨ作動性浸透破裂放出用製剤 | |
| DK174992B1 (da) | Farmaceutisk præparat med langsom frigivelse samt anvendelse af visse additiver i sådanne til opnåelse af langsom frigivelse | |
| US3148124A (en) | Method of preparing sustained release pharmaceutical tablets | |
| JPH06172398A (ja) | ゼイン水性分散液およびそれから得られた制御放出コーティング | |
| CA2556514C (en) | Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same | |
| JPH0237327B2 (ru) | ||
| JP2002505274A (ja) | 長期放出剤形 | |
| JPH08507087A (ja) | 蒸気透過性コーチングを有する浸透デバイス | |
| JP2001515456A (ja) | 口腔の苦痛状態を治療するための経口投与および方法 | |
| CA1041905A (en) | Integral solid gel-lattice dosage form of high moisture content | |
| IL102778A (en) | Controlled-release preparations with a spheroidal nucleus and a process for their preparation | |
| JPH09509412A (ja) | ２層アモキシシリン錠剤 | |
| US4267138A (en) | Coating ensuring a controlled release of active ingredients of biologically active compositions, particularly pharmaceutical compositions and a process for preparation of biologically active compositions ensuring controlled release of active ingredients | |
| EP0250083B1 (en) | Dosage form with means for governing rate of gas formation | |
| US5322698A (en) | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure | |
| RU96120083A (ru) | Гранулированный продукт или таблетка, содержащие шипучую систему и активное фармацевтическое средство, а также способ их получения | |
| PL145663B1 (en) | Method of obtaining sustained-action drug tablets | |
| RU2488396C2 (ru) | Тонкие гранулы, имеющие улучшенные характеристики в водной суспензии | |
| KR890004683B1 (ko) | 클로로페니라민 제형 | |
| JP2006507298A (ja) | 経口持続放出型錠剤、ならびにその製造法および使用法 | |
| WO1999042087A2 (en) | Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content |